Bio-Thera Solutions, Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 688177.SS | 688382.SS | 2509.HK | BHVN | SMZ1.F | 8SJ.F | |
|---|---|---|---|---|---|---|
| Market cap | 7.38B | 8.38B | 3.31B | 2.30B | 11.09B | 1.84B |
| P/E (TTM) | — | — | 5.4 | — | 31.2 | — |
| Forward P/E | -26.2 | -43.8 | 18.3 | -8.2 | — | — |
| Price/book | 171.3 | 6.6 | 3.3 | -23.4 | 2.6 | 2.4 |
| Dividend yield | — | — | — | — | 2.90% | — |
| 1-year change | −34.43% | −48.70% | −36.17% | +78.66% | −23.60% | −37.59% |
| Today | +2.95% | +4.33% | −0.40% | −2.37% | +1.45% | +1.70% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 688177.SS news ›First Biosimilar Secukinumab Approved in China for Bio-Thera Solutions
Home / News / BioBlast® BAT2306/Youzhuomei™ is approved for psoriasis, ankylosing spondylitis and psoriatic arthritis. Cosentyx® is approved in China for the treatment of plaque psoriasis in patients aged 6 years and older; and for…
Bio-Thera Solutions and Avalon Pharma are deepening their collaboration on BAT2406 in Saudi Arabia and other Middle Eastern and North African markets
Bio-Thera Solutions, Ltd. announced a deepened collaboration with Avalon Pharmaceuticals on BAT2406, a biosimilar of Dupixent dupilumab, in Saudi Arabia and other Middle Eastern and North African... announced a deepened collaboration with…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.